The FDA’s over-reliance on guidance documents is undercutting traditional notice-and-comment rulemaking and hurting industry, one advocacy group warns.
The Washington Legal Foundation, a free-market advocacy group and think tank, is charging that the Food and Drug Administration is leaning too heavily on guidance documents in lieu of regulations, undercutting the Administrative Procedure Act and causing excessive burdens on affected industries. The group said the FDA has released more than 2,000 guidance documents and draft documents, far too many for industry to keep track of.
“The reason for this trend is obvious: Formal rulemaking can be quite cumbersome, and FDA would prefer, when possible, to avoid the time and expense involved,” the group wrote to the FDA in response to a comment request.
William Garvin, a Washington-based life sciences attorney at Buchanan Ingersoll & Rooney PC, told me that the FDA might be pushing guidance-based requirements too far.
“It gives the agency flexibility to change their position if the situation changes,” he said. “So in general, the use of guidances is an important tool for the FDA that can be subject to abuse.”
It is hard to determine the FDA’s endgame for the request, Stephanie Philbin of Goodwin Procter LLP in Washington told me.
“We will see some changes coming out of this effort, but what the extent and depth of the changes are to be determined,” she said. Philbin, a counsel in the firm’s FDA group, is a Bloomberg Law advisory board member.
The Washington Legal Foundation also argued that cutting the use of guidance documents could be an important step in complying with the White House’s deregulation mandate.
Read my full article here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)